{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Methods.: A phase 2a, randomized, multicenter, open-label study of adult recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Methods.: A phase 2a, randomized, multicenter, open-label study"
      },
      "Participants": {
        "score": 2,
        "evidence": "adult recipients (aged \u226518 y) of a living or deceased donor kidney transplant with a history of biopsy-proven primary FSGS"
      },
      "Intervention": {
        "score": 2,
        "evidence": "bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression in the prevention of rFSGS >12 mo posttransplantation, versus standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids"
      },
      "Objective": {
        "score": 1,
        "evidence": "The study assessed the efficacy of bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression in the prevention of rFSGS"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was rFSGS, defined as proteinuria (protein-creatinine ratio \u22653.0\u2009g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, through 3 mo posttransplant"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 1,
        "evidence": "open-label study"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Sixty-three patients were followed for 12 mo posttransplantation"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Relative decrease in rFSGS occurrence through 3 mo with bleselumab versus SOC was 40.7% (95% confidence interval, \u221289.8 to 26.8; P = 0.37; absolute decrease 12.7% [95% confidence interval, \u221234.5 to 9.0])"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar for both treatments"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  },
  "model": "gpt-4o"
}